NIH pours $3M into portable brain injury scanner from Neural Analytics

Stroke and brain injury diagnostic specialist Neural Analytics scored a $3 million cash infusion from the National Institutes of Health to help fund the development of a portable brain monitoring platform.

LA-based Neural Analytics, which began its operation in 2013, focuses on brain conditions such as traumatic injury, acute ischemic stroke and dementia. The company licensed technology from UCLA to screen for these conditions and is working to commercialize its products.

The funding will go toward a clinical validation study of its main development: a wearable device that uses ultrasound to detect abnormalities in the brain. The idea is to have first responders and emergency room physicians use the device to assess mild to severe traumatic brain injury on the go, when it is most important to act quickly.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

And as a portable device, Neural Analytics’ tech enters a field that has garnered significant attention because of sports injuries, particularly in football. The company’s website features images of football players, bikers and American soldiers to imply future uses.

“We need a portable tool to effectively look inside the brain and determine the extent of disease to help us significantly advance brain health in the 21st century,” UCLA chief of neurosurgery Neil Martin, who is a clinical adviser to Neural Analytics, said. “When approved by the FDA, these types of portable devices will revolutionize medical care by assisting physicians and first responders to quickly evaluate brain health and expedite treatment for many patients.”

In December last year, the company picked up a $10 million Series A round to back clinical testing and development of the device.

Suggested Articles

Philips is cementing its commitment to becoming a healthcare technology provider, with plans to split off or sell its consumer appliances division.

Joe Jimenez has (another) new gig. The ex-Novartis boss joined the board of Century Therapeutics, a startup working on off-the-shelf cell therapies.

As Pfizer posts its full-year financials today, as usual it’s also sneaked in several dropped projects from its pipeline.